investor_presentation
Adriatic Metals
Loading viewer...
investor_presentation
Format: PDF investor_presentation
Targetin g Disease at the Nuclear Po re Corporate Presentation September 2019
Targetin g Disease at the Nuclear Po re
Corporate Presentation
September 2019 2Forward -looking Statements and Other Important Information
This presentation contains forward -looking statements within themeaning ofthe“safe harbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such
forward -looking statements include those regarding thetherapeutic potential ofand potential clinical development plans and commercialization forKaryopharm’s drug
candidates, including thetiming ofinitiation ofcertain trials, ofthereporting ofdata from such trials, ofthesubmissions toregulatory authorities andofpotential commercial
launches, thepotential availability ofaccelerated approval pathways, thepotential sizeofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment of
patients with relapsed multiple myeloma andKaryopharm’s strategic andfinancial plans andexpectations aswellasfinancial projections forKaryopharm .Such statements
aresubject tonumerous important factors, risks anduncertainties thatmay cause actual events orresults todiffer materially from Karyopharm’s current expectations .For
example, there canbenoguarantee thatregulators willagree thatselinexor qualifies forconditional approval intheE.U.asaresult ofthedata from theSTORM study in
patients withpenta -refractory myeloma oraccelerated approval intheU.S.based ontheSADAL study inpatients withrelapsed/refractory DLBCL orthatanyofKaryopharm’s
drug candidates, including selinexor andeltanexor (KPT -8602 ),Karyopharm’s second generation SINE compound, orKPT-9274 ,Karyopharm’s first-in-class oraldual inhibitor
ofPAK4and NAMPT, oranyother drug candidate Karyopharm isdeveloping, willsuccessfully complete necessary preclinical and clinical development phases orthat
development ofanyofKaryopharm’s drug candidates willcontinue .Further, there canbenoguarantee that anypositive developments inKaryopharm’s drug candidate
portfolio willresult instock price appreciation .Inaddition, even ifKaryopharm receives marketing approval forselinexor oranother drug candidate, there canbenoassurance
that Karyopharm willbeable tosuccessfully commercialize that drug candidate .Management’s expectations and, therefore ,any forward -looking statements inthis
presentation could also beaffected byrisks anduncertainties relating toanumber ofother factors, many ofwhich arebeyond Karyopharm’s control, including thefollowing :the
timing andcosts involved incommercializing XPOVIO oranyofKaryopharm’s drug candidates thatreceive regulatory approval ;theability toretain regulatory approval of
XPOVIO oranyofKaryopharm’s drug candidates thatreceive regulatory approval ;Karyopharm’s results ofclinical trials andpreclinical studies, including subsequent analysis
ofexisting data andnew data received from ongoing andfuture studies ;thecontent andtiming ofdecisions made bytheFDA andother regulatory authorities, investigational
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
31 Pages
Exro Technologies Inc.
investor_presentation
Adriatic Metals
Iovance Biotherapeutics Investor Presentation — November 2021
investor_presentationinvestor_presentation
50 Pages
Iovance Biotherapeutics, Inc